3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
4
Neoplasms
2
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Oligodendroglioma
1
Metastatic Castration-resistant Prostate Cancer
1
Malignant Solid Tumor - Malignant Nervous System Neoplasm
1
Lymphadenopathy
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Carcinoma
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
pembrolizumab
12
Cisplatin
5
Cetuximab
5
Paclitaxel
4
durvalumab
3
Nivolumab
3
Ipilimumab
3
Gemcitabine
3
Cyclophosphamide
3
poly ICLC
2
avelumab
2
Radiation
2
Pemetrexed
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vistusertib
1
tislelizumab
1
tirbanibulin
1
spartalizumab
1
sonidegib
1
sitravatinib
1
repotrectinib
1
pralsetinib
1
pertuzumab
1
pepinemab
1
obinutuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma
×
cabazitaxel
×
Clear all
NCT02202772
2025-02-24
CGC
Columbia University
Phase 1/2
Active not recruiting
51 enrolled